<?xml version="1.0" encoding="utf-8"?><api:response xmlns:api="http://www.symplectic.co.uk/publications/api"><api:version uri="https://mypublications.shef.ac.uk/" elements-version="6.15.0.3976" schema-version="6.13" product-name="myPublications"/><api:request href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/851"/><api:result><api:object category="publication" id="851" last-affected-when="2024-03-14T05:57:34.247+00:00" last-modified-when="2024-03-14T05:57:34.247+00:00" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/851" created-when="2010-05-17T13:46:30.783+01:00" type-id="5" type-display-name="Journal article" type="journal-article"><api:privacy-level>Public</api:privacy-level><api:privacy-level-locked>false</api:privacy-level-locked><api:ever-approved>true</api:ever-approved><api:reporting-date-1>2000-04-01</api:reporting-date-1><api:allow-type-switching>true</api:allow-type-switching><api:records><api:record format="native" id="1484393" source-id="13" source-name="crossref" source-display-name="Crossref" id-at-source="10.1016/S0264-410X(99)00567-8" last-modified-when="2023-04-22T22:25:30.27+01:00"><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Mohamedi</api:last-name><api:initials>SA</api:initials><api:first-names>SA</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Brewer</api:last-name><api:initials>JM</api:initials><api:first-names>JM</api:first-names><api:separate-first-names><api:first-name>J</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Alexander</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="2047" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2047"/></api:links><api:last-name>Heath</api:last-name><api:initials>AW</api:initials><api:first-names>AW</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>W</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Jennings</api:last-name><api:initials>R</api:initials><api:first-names>R</api:first-names><api:separate-first-names><api:first-name>R</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1016/s0264-410x(99)00567-8</api:text><api:links><api:link type="doi" href="http://doi.org/10.1016/s0264-410x(99)00567-8"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1016/s0264-410x(99)00567-8"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0264-410X</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/976912"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>20</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Vaccine</api:text></api:field><api:field name="language" type="text" display-name="Language"><api:text>en</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>2083</api:begin-page><api:end-page>2094</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>4</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Elsevier BV</api:text></api:field><api:field name="publisher-url" type="text" display-name="Link 2"><api:text>http://dx.doi.org/10.1016/s0264-410x(99)00567-8</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>16</api:day><api:month>4</api:month><api:year>2023</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>18</api:text></api:field></api:native></api:record><api:record format="native" id="95827" source-id="7" source-name="scopus" source-display-name="Scopus" id-at-source="2-s2.0-0034014199" last-modified-when="2021-12-22T08:11:53.883+00:00"><api:citation-count>17</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>The immunogenicity of a type 2 herpes simplex virus (HSV-2) antigen preparation following its formulation into immunostimulating complexes (ISCOMs) or non-ionic surfactant vesicles (NISV) was investigated in a murine model. The immune responses induced by each formulation were characterised by antigen specific total and subclass serum responses, and by lymphocyte proliferation and cytokine (interleukin-2 (IL-2), interleukin-4 (IL-4) and interferon-gamma (IFN-γ)) production by in vitro restimulated spleen cells. The degree of protection afforded to mice by these various HSV-2 vaccine preparations against homologous (HSV-2) and heterologous (HSV-1) challenge infection was also determined. The findings suggest that formulation of the HSV-2 glycoprotein antigens with ISCOM or NISV delivery vehicles, and the methods used to prepare these formulations, influenced the immunogenicity of the final preparation. Higher IgG2a and neutralising antibody levels, IL-2 and IFN-γ levels and lymphoproliferative responses were noted in mice immunised with the HSV-2 ISCOM formulated vaccine preparation. Furthermore, although HSV-2 antigens formulated in dehydration-rehydration NISV, or entrapped in NISV by freeze-thawing at 30°C (HSV-2 NISV 30), also elicited relatively high antibody, IL-2 and IFN-γ levels and relatively high lymphoproliferative responses, formulation of HSV-2 antigens by freeze-thawing with NISV at 60°C (HSV-2 NISV 60) did not. There were no differences between any of the HSV-2 vaccine formulations in terms of IL-4 induction in in vitro stimulated spleen cell cultures. Almost complete protection against HSV-2 challenge was afforded by the HSV-2 ISCOM preparation, while partial protection against challenge infection was afforded by the HSV-2 NISV 30 vaccine formulation. The findings are discussed in relation to the nature of the immune mechanisms, particularly Th1- or Th2-like responses, that may be elicited by HSV-2 antigen preparations formulated into various delivery systems and the relevance of these immune responses to protection against HSV infection in the murine model. Copyright (C) 2000 Elsevier Science Ltd.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Mohamedi</api:last-name><api:initials>SA</api:initials><api:first-names>SA</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>A</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Sheffield Inst. for Vaccine Studies</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">56628367900</api:identifier></api:identifiers></api:person><api:person><api:last-name>Brewer</api:last-name><api:initials>JM</api:initials><api:first-names>JM</api:first-names><api:separate-first-names><api:first-name>J</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">University of Strathclyde</api:line><api:line type="city">Glasgow</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7201421409</api:identifier></api:identifiers></api:person><api:person><api:last-name>Alexander</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">University of Strathclyde</api:line><api:line type="city">Glasgow</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7404459076</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="2047" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2047"/></api:links><api:last-name>Heath</api:last-name><api:initials>AW</api:initials><api:first-names>AW</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>W</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Sheffield Inst. for Vaccine Studies</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7201835305</api:identifier></api:identifiers></api:person><api:person><api:last-name>Jennings</api:last-name><api:initials>R</api:initials><api:first-names>R</api:first-names><api:separate-first-names><api:first-name>R</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Sheffield Inst. for Vaccine Studies</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7201971819</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1016/S0264-410X(99)00567-8</api:text><api:links><api:link type="doi" href="http://doi.org/10.1016/S0264-410X(99)00567-8"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1016/S0264-410X(99)00567-8"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10715522</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0264-410X</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/976912"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>20</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Vaccine</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>2083</api:begin-page><api:end-page>2094</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>1</api:day><api:month>4</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>18</api:text></api:field></api:native></api:record><api:record format="native" id="851" source-id="2" source-name="pubmed" source-display-name="PubMed" id-at-source="10715522" last-modified-when="2020-04-29T04:26:28.163+01:00"><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>The immunogenicity of a type 2 herpes simplex virus (HSV-2) antigen preparation following its formulation into immunostimulating complexes (ISCOMs) or non-ionic surfactant vesicles (NISV) was investigated in a murine model. The immune responses induced by each formulation were characterised by antigen specific total and subclass serum responses, and by lymphocyte proliferation and cytokine (interleukin-2 (IL-2), interleukin-4 (IL-4) and interferon-gamma (IFN-gamma)) production by in vitro restimulated spleen cells. The degree of protection afforded to mice by these various HSV-2 vaccine preparations against homologous (HSV-2) and heterologous (HSV-1) challenge infection was also determined. The findings suggest that formulation of the HSV-2 glycoprotein antigens with ISCOM or NISV delivery vehicles, and the methods used to prepare these formulations, influenced the immunogenicity of the final preparation. Higher IgG2a and neutralising antibody levels, IL-2 and IFN-gamma levels and lymphoproliferative responses were noted in mice immunised with the HSV-2 ISCOM formulated vaccine preparation. Furthermore, although HSV-2 antigens formulated in dehydration-rehydration NISV, or entrapped in NISV by freeze-thawing at 30 degrees C (HSV-2 NISV 30), also elicited relatively high antibody, IL-2 and IFN-gamma levels and relatively high lymphoproliferative responses, formulation of HSV-2 antigens by freeze-thawing with NISV at 60 degrees C (HSV-2 NISV 60) did not. There were no differences between any of the HSV-2 vaccine formulations in terms of IL-4 induction in in vitro stimulated spleen cell cultures. Almost complete protection against HSV-2 challenge was afforded by the HSV-2 ISCOM preparation, while partial protection against challenge infection was afforded by the HSV-2 NISV 30 vaccine formulation. The findings are discussed in relation to the nature of the immune mechanisms, particularly Th1- or Th2-like responses, that may be elicited by HSV-2 antigen preparations formulated into various delivery systems and the relevance of these immune responses to protection against HSV infection in the murine model.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Mohamedi</api:last-name><api:initials>SA</api:initials><api:first-names>SA</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>A</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="full">Sheffield Institute for Vaccine Studies, Division of Molecular and Genetic Medicine, Floor 'F', University of Sheffield Medical School, Beech Hill Road, Sheffield, UK.</api:line></api:address></api:addresses></api:person><api:person><api:last-name>Brewer</api:last-name><api:initials>JM</api:initials><api:first-names>JM</api:first-names><api:separate-first-names><api:first-name>J</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Alexander</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="2047" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2047"/></api:links><api:last-name>Heath</api:last-name><api:initials>AW</api:initials><api:first-names>AW</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>W</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Jennings</api:last-name><api:initials>R</api:initials><api:first-names>R</api:first-names><api:separate-first-names><api:first-name>R</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.ncbi.nlm.nih.gov/pubmed/10715522</api:text></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1016/s0264-410x(99)00567-8</api:text><api:links><api:link type="doi" href="http://doi.org/10.1016/s0264-410x(99)00567-8"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1016/s0264-410x(99)00567-8"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0264-410X</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/976912"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>20</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Vaccine</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Administration, Oral</api:keyword><api:keyword scheme="mesh">Animals</api:keyword><api:keyword scheme="mesh">Antibodies, Viral</api:keyword><api:keyword scheme="mesh">Antigen Presentation</api:keyword><api:keyword scheme="mesh">Antigens, Viral</api:keyword><api:keyword scheme="mesh">CD8-Positive T-Lymphocytes</api:keyword><api:keyword scheme="mesh">Cells, Cultured</api:keyword><api:keyword scheme="mesh">Chlorocebus aethiops</api:keyword><api:keyword scheme="mesh">Cytokines</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Herpes Simplex</api:keyword><api:keyword scheme="mesh">ISCOMs</api:keyword><api:keyword scheme="mesh">Immunization, Secondary</api:keyword><api:keyword scheme="mesh">Immunoglobulin G</api:keyword><api:keyword scheme="mesh">Lymphocyte Activation</api:keyword><api:keyword scheme="mesh">Mice</api:keyword><api:keyword scheme="mesh">Mice, Inbred BALB C</api:keyword><api:keyword scheme="mesh">Simplexvirus</api:keyword><api:keyword scheme="mesh">Spleen</api:keyword><api:keyword scheme="mesh">Surface-Active Agents</api:keyword><api:keyword scheme="mesh">Vaccination</api:keyword><api:keyword scheme="mesh">Vero Cells</api:keyword><api:keyword scheme="mesh">Viral Vaccines</api:keyword><api:keyword scheme="mesh">Virus Cultivation</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="location" type="text" display-name="Country"><api:text>Netherlands</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>2083</api:begin-page><api:end-page>2094</api:end-page></api:pagination></api:field><api:field name="pii" type="text" display-name="PII"><api:text>S0264-410X(99)00567-8</api:text></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>14</api:day><api:month>4</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-made-public-at-source-date" type="date" display-name="Record made publicly available"><api:date><api:day>11</api:day><api:month>7</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Comparative Study</api:item><api:item>Journal Article</api:item><api:item>Research Support, Non-U.S. Gov't</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>18</api:text></api:field></api:native></api:record><api:record format="native" id="882094" source-id="18" source-name="epmc" source-display-name="Europe PubMed Central" id-at-source="MED:10715522" last-modified-when="2021-01-19T17:56:35.85+00:00"><api:citation-count>10</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>The immunogenicity of a type 2 herpes simplex virus (HSV-2) antigen preparation following its formulation into immunostimulating complexes (ISCOMs) or non-ionic surfactant vesicles (NISV) was investigated in a murine model. The immune responses induced by each formulation were characterised by antigen specific total and subclass serum responses, and by lymphocyte proliferation and cytokine (interleukin-2 (IL-2), interleukin-4 (IL-4) and interferon-gamma (IFN-gamma)) production by in vitro restimulated spleen cells. The degree of protection afforded to mice by these various HSV-2 vaccine preparations against homologous (HSV-2) and heterologous (HSV-1) challenge infection was also determined. The findings suggest that formulation of the HSV-2 glycoprotein antigens with ISCOM or NISV delivery vehicles, and the methods used to prepare these formulations, influenced the immunogenicity of the final preparation. Higher IgG2a and neutralising antibody levels, IL-2 and IFN-gamma levels and lymphoproliferative responses were noted in mice immunised with the HSV-2 ISCOM formulated vaccine preparation. Furthermore, although HSV-2 antigens formulated in dehydration-rehydration NISV, or entrapped in NISV by freeze-thawing at 30 degrees C (HSV-2 NISV 30), also elicited relatively high antibody, IL-2 and IFN-gamma levels and relatively high lymphoproliferative responses, formulation of HSV-2 antigens by freeze-thawing with NISV at 60 degrees C (HSV-2 NISV 60) did not. There were no differences between any of the HSV-2 vaccine formulations in terms of IL-4 induction in in vitro stimulated spleen cell cultures. Almost complete protection against HSV-2 challenge was afforded by the HSV-2 ISCOM preparation, while partial protection against challenge infection was afforded by the HSV-2 NISV 30 vaccine formulation. The findings are discussed in relation to the nature of the immune mechanisms, particularly Th1- or Th2-like responses, that may be elicited by HSV-2 antigen preparations formulated into various delivery systems and the relevance of these immune responses to protection against HSV infection in the murine model.</api:text></api:field><api:field name="addresses" type="address-list" display-name="Addresses"><api:addresses><api:address iso-country-code="GB"><api:line type="full">Sheffield Institute for Vaccine Studies, Division of Molecular and Genetic Medicine, Floor 'F', University of Sheffield Medical School, Beech Hill Road, Sheffield, UK.</api:line></api:address></api:addresses></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Mohamedi</api:last-name><api:initials>SA</api:initials><api:first-names>SA</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Brewer</api:last-name><api:initials>JM</api:initials><api:first-names>JM</api:first-names><api:separate-first-names><api:first-name>J</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="orcid">0000-0001-7933-0915</api:identifier></api:identifiers></api:person><api:person><api:last-name>Alexander</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="2047" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2047"/></api:links><api:last-name>Heath</api:last-name><api:initials>AW</api:initials><api:first-names>AW</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>W</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Jennings</api:last-name><api:initials>R</api:initials><api:first-names>R</api:first-names><api:separate-first-names><api:first-name>R</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1016/s0264-410x(99)00567-8</api:text><api:links><api:link type="doi" href="http://doi.org/10.1016/s0264-410x(99)00567-8"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1016/s0264-410x(99)00567-8"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1873-2518</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/976912"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10715522</api:identifier></api:identifiers></api:field><api:field name="is-open-access" type="boolean" display-name="Open access"><api:boolean>false</api:boolean></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0264-410X</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/976912"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>20</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Vaccine</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Spleen</api:keyword><api:keyword scheme="mesh">CD8-Positive T-Lymphocytes</api:keyword><api:keyword scheme="mesh">Cells, Cultured</api:keyword><api:keyword scheme="mesh">Vero Cells</api:keyword><api:keyword scheme="mesh">Animals</api:keyword><api:keyword scheme="mesh">Mice, Inbred BALB C</api:keyword><api:keyword scheme="mesh">Mice</api:keyword><api:keyword scheme="mesh">Simplexvirus</api:keyword><api:keyword scheme="mesh">Herpes Simplex</api:keyword><api:keyword scheme="mesh">Immunoglobulin G</api:keyword><api:keyword scheme="mesh">ISCOMs</api:keyword><api:keyword scheme="mesh">Viral Vaccines</api:keyword><api:keyword scheme="mesh">Antibodies, Viral</api:keyword><api:keyword scheme="mesh">Antigens, Viral</api:keyword><api:keyword scheme="mesh">Cytokines</api:keyword><api:keyword scheme="mesh">Surface-Active Agents</api:keyword><api:keyword scheme="mesh">Immunization, Secondary</api:keyword><api:keyword scheme="mesh">Vaccination</api:keyword><api:keyword scheme="mesh">Virus Cultivation</api:keyword><api:keyword scheme="mesh">Administration, Oral</api:keyword><api:keyword scheme="mesh">Lymphocyte Activation</api:keyword><api:keyword scheme="mesh">Antigen Presentation</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Chlorocebus aethiops</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="medium" type="text" display-name="Medium"><api:text>Print</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>2083</api:begin-page><api:end-page>2094</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>4</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>15</api:day><api:month>3</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Comparative Study</api:item><api:item>Research Support, Non-U.S. Gov't</api:item><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>18</api:text></api:field></api:native></api:record><api:record format="native" id="2507149" source-id="10" source-name="dimensions" source-display-name="Dimensions" id-at-source="pub.1015528680" last-modified-when="2024-02-05T02:25:05.787+00:00"><api:citation-count>16</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Mohamedi</api:last-name><api:initials>SA</api:initials><api:first-names>SA</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>A</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">University of Sheffield</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01246601362.08</api:identifier></api:identifiers></api:person><api:person><api:last-name>Brewer</api:last-name><api:initials>JM</api:initials><api:first-names>JM</api:first-names><api:separate-first-names><api:first-name>J</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">University of Strathclyde</api:line><api:line type="city">Glasgow</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.015443300632.67</api:identifier></api:identifiers></api:person><api:person><api:last-name>Alexander</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">University of Strathclyde</api:line><api:line type="city">Glasgow</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0676752131.60</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="2047" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2047"/></api:links><api:last-name>Heath</api:last-name><api:initials>AW</api:initials><api:first-names>AW</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>W</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">University of Sheffield</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0657140264.85</api:identifier></api:identifiers></api:person><api:person><api:last-name>Jennings</api:last-name><api:initials>R</api:initials><api:first-names>R</api:first-names><api:separate-first-names><api:first-name>R</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">University of Sheffield</api:line><api:line type="city">Sheffield</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01164605622.09</api:identifier></api:identifiers><api:author-types><api:author-type>corresponding</api:author-type></api:author-types></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1016/s0264-410x(99)00567-8</api:text><api:links><api:link type="doi" href="http://doi.org/10.1016/s0264-410x(99)00567-8"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1016/s0264-410x(99)00567-8"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10715522</api:identifier></api:identifiers></api:field><api:field name="field-citation-ratio" type="decimal" display-name="Field citation ratio"><api:decimal>1.51</api:decimal></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0264-410X</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/976912"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>20</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Vaccine</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="for-2020">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020">3204 Immunology</api:keyword><api:keyword scheme="rcdc">Vaccine Related</api:keyword><api:keyword scheme="rcdc">Infectious Diseases</api:keyword><api:keyword scheme="rcdc">Prevention</api:keyword><api:keyword scheme="rcdc">Biotechnology</api:keyword><api:keyword scheme="rcdc">Sexually Transmitted Infections</api:keyword><api:keyword scheme="rcdc">Immunization</api:keyword><api:keyword scheme="hrcs-hc">Infection</api:keyword><api:keyword scheme="hrcs-hc">Inflammatory and immune system</api:keyword><api:keyword scheme="mesh">Administration, Oral</api:keyword><api:keyword scheme="mesh">Animals</api:keyword><api:keyword scheme="mesh">Antibodies, Viral</api:keyword><api:keyword scheme="mesh">Antigen Presentation</api:keyword><api:keyword scheme="mesh">Antigens, Viral</api:keyword><api:keyword scheme="mesh">CD8-Positive T-Lymphocytes</api:keyword><api:keyword scheme="mesh">Cells, Cultured</api:keyword><api:keyword scheme="mesh">Chlorocebus aethiops</api:keyword><api:keyword scheme="mesh">Cytokines</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Herpes Simplex</api:keyword><api:keyword scheme="mesh">ISCOMs</api:keyword><api:keyword scheme="mesh">Immunization, Secondary</api:keyword><api:keyword scheme="mesh">Immunoglobulin G</api:keyword><api:keyword scheme="mesh">Lymphocyte Activation</api:keyword><api:keyword scheme="mesh">Mice</api:keyword><api:keyword scheme="mesh">Mice, Inbred BALB C</api:keyword><api:keyword scheme="mesh">Simplexvirus</api:keyword><api:keyword scheme="mesh">Spleen</api:keyword><api:keyword scheme="mesh">Surface-Active Agents</api:keyword><api:keyword scheme="mesh">Vaccination</api:keyword><api:keyword scheme="mesh">Vero Cells</api:keyword><api:keyword scheme="mesh">Viral Vaccines</api:keyword><api:keyword scheme="mesh">Virus Cultivation</api:keyword></api:keywords></api:field><api:field name="open-access-status" type="text" display-name="Open access status"><api:text>Closed Access</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>2083</api:begin-page><api:end-page>2094</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>4</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Elsevier</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>31</api:day><api:month>8</api:month><api:year>2017</api:year></api:date></api:field><api:field name="relative-citation-ratio" type="decimal" display-name="Relative citation ratio"><api:decimal>0.28</api:decimal></api:field><api:field name="title" type="text" display-name="Title"><api:text>Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>18</api:text></api:field></api:native></api:record><api:record format="native" id="241505" source-id="11" source-name="wos-lite" source-display-name="Web of Science (Lite)" id-at-source="WOS:000086404900003" last-modified-when="2024-03-14T05:57:34.25+00:00"><api:citation-count>15</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Mohamedi</api:last-name><api:initials>SA</api:initials><api:first-names>SA</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Brewer</api:last-name><api:initials>JM</api:initials><api:first-names>JM</api:first-names><api:separate-first-names><api:first-name>J</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="researcherid">A-7186-2010</api:identifier></api:identifiers></api:person><api:person><api:last-name>Alexander</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names><api:identifiers><api:identifier scheme="researcherid">A-4238-2009</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="2047" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2047"/></api:links><api:last-name>Heath</api:last-name><api:initials>AW</api:initials><api:first-names>AW</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>W</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Jennings</api:last-name><api:initials>R</api:initials><api:first-names>R</api:first-names><api:separate-first-names><api:first-name>R</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.webofscience.com/api/gateway?GWVersion=2&amp;SrcApp=sheffield_elements_live&amp;SrcAuth=WosAPI&amp;KeyUT=WOS:000086404900003&amp;DestLinkType=FullRecord&amp;DestApp=WOS_CPL</api:text></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1016/S0264-410X(99)00567-8</api:text><api:links><api:link type="doi" href="http://doi.org/10.1016/S0264-410X(99)00567-8"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1016/S0264-410X(99)00567-8"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1873-2518</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/976912"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="isidoc">303DE</api:identifier><api:identifier scheme="pubmed">10715522</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0264-410X</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/976912"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>20</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>VACCINE</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>HSV-2 vaccine</api:keyword><api:keyword>immunostimulating complexes (ISCOMs)</api:keyword><api:keyword>non-ionic surfactant vesicles (NISV)</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>2083</api:begin-page><api:end-page>2094</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>18</api:text></api:field></api:native></api:record><api:record format="native" id="24498" source-id="3" source-name="wos" source-display-name="Web of Science" id-at-source="WOS:000086404900003" last-modified-when="2014-07-25T11:06:02.453+01:00"><api:citation-count>10</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Mohamedi</api:last-name><api:initials>SA</api:initials><api:first-names>SA</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Brewer</api:last-name><api:initials>JM</api:initials><api:first-names>JM</api:first-names><api:separate-first-names><api:first-name>J</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Alexander</api:last-name><api:initials>J</api:initials><api:first-names>J</api:first-names><api:separate-first-names><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="2047" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/2047"/></api:links><api:last-name>Heath</api:last-name><api:initials>AW</api:initials><api:first-names>AW</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>W</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Jennings</api:last-name><api:initials>R</api:initials><api:first-names>R</api:first-names><api:separate-first-names><api:first-name>R</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0264-410X</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/976912"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>20</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>VACCINE</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>HSV-2 vaccine</api:keyword><api:keyword>immunostimulating complexes (ISCOMs)</api:keyword><api:keyword>non-ionic surfactant vesicles (NISV)</api:keyword><api:keyword>HERPES-SIMPLEX VIRUS</api:keyword><api:keyword>HUMAN-IMMUNODEFICIENCY-VIRUS</api:keyword><api:keyword>T-CELL SUBSETS</api:keyword><api:keyword>INTERFERON-GAMMA</api:keyword><api:keyword>GENITAL HERPES</api:keyword><api:keyword>IN-VIVO</api:keyword><api:keyword>MONOCLONAL-ANTIBODIES</api:keyword><api:keyword>NERVOUS-SYSTEM</api:keyword><api:keyword>PARENTERAL IMMUNIZATION</api:keyword><api:keyword>ADJUVANT ACTIVITY</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>2083</api:begin-page><api:end-page>2094</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>14</api:day><api:month>4</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Antibody responses, cytokine levels and protection of mice immunised with HSV-2 antigens formulated into NISV or ISCOM delivery systems</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>18</api:text></api:field></api:native></api:record></api:records><api:fields/><api:all-labels type="keyword-list"><api:keywords><api:keyword scheme="mesh" origin="record-data" source="pubmed">Administration, Oral</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Animals</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Antibodies, Viral</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Antigen Presentation</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Antigens, Viral</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">CD8-Positive T-Lymphocytes</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Cells, Cultured</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Chlorocebus aethiops</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Cytokines</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Herpes Simplex</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">ISCOMs</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Immunization, Secondary</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Immunoglobulin G</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Lymphocyte Activation</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Mice</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Mice, Inbred BALB C</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Simplexvirus</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Spleen</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Surface-Active Agents</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Vaccination</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Vero Cells</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Viral Vaccines</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Virus Cultivation</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Spleen</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">CD8-Positive T-Lymphocytes</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Cells, Cultured</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Vero Cells</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Animals</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Mice, Inbred BALB C</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Mice</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Simplexvirus</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Herpes Simplex</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Immunoglobulin G</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">ISCOMs</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Viral Vaccines</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Antibodies, Viral</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Antigens, Viral</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Cytokines</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Surface-Active Agents</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Immunization, Secondary</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Vaccination</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Virus Cultivation</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Administration, Oral</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Lymphocyte Activation</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Antigen Presentation</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Chlorocebus aethiops</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3204 Immunology</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Vaccine Related</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Infectious Diseases</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Prevention</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Biotechnology</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Sexually Transmitted Infections</api:keyword><api:keyword scheme="rcdc" origin="record-data" source="dimensions">Immunization</api:keyword><api:keyword scheme="hrcs-hc" origin="record-data" source="dimensions">Infection</api:keyword><api:keyword scheme="hrcs-hc" origin="record-data" source="dimensions">Inflammatory and immune system</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Administration, Oral</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Animals</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Antibodies, Viral</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Antigen Presentation</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Antigens, Viral</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">CD8-Positive T-Lymphocytes</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Cells, Cultured</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Chlorocebus aethiops</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Cytokines</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Herpes Simplex</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">ISCOMs</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Immunization, Secondary</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Immunoglobulin G</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Lymphocyte Activation</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Mice</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Mice, Inbred BALB C</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Simplexvirus</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Spleen</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Surface-Active Agents</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Vaccination</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Vero Cells</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Viral Vaccines</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Virus Cultivation</api:keyword><api:keyword origin="record-data" source="wos-lite">HSV-2 vaccine</api:keyword><api:keyword origin="record-data" source="wos-lite">immunostimulating complexes (ISCOMs)</api:keyword><api:keyword origin="record-data" source="wos-lite">non-ionic surfactant vesicles (NISV)</api:keyword><api:keyword origin="record-data" source="wos">HSV-2 vaccine</api:keyword><api:keyword origin="record-data" source="wos">immunostimulating complexes (ISCOMs)</api:keyword><api:keyword origin="record-data" source="wos">non-ionic surfactant vesicles (NISV)</api:keyword><api:keyword origin="record-data" source="wos">HERPES-SIMPLEX VIRUS</api:keyword><api:keyword origin="record-data" source="wos">HUMAN-IMMUNODEFICIENCY-VIRUS</api:keyword><api:keyword origin="record-data" source="wos">T-CELL SUBSETS</api:keyword><api:keyword origin="record-data" source="wos">INTERFERON-GAMMA</api:keyword><api:keyword origin="record-data" source="wos">GENITAL HERPES</api:keyword><api:keyword origin="record-data" source="wos">IN-VIVO</api:keyword><api:keyword origin="record-data" source="wos">MONOCLONAL-ANTIBODIES</api:keyword><api:keyword origin="record-data" source="wos">NERVOUS-SYSTEM</api:keyword><api:keyword origin="record-data" source="wos">PARENTERAL IMMUNIZATION</api:keyword><api:keyword origin="record-data" source="wos">ADJUVANT ACTIVITY</api:keyword><api:keyword scheme="for" origin="issn-inferred">06 Biological Sciences</api:keyword><api:keyword scheme="for" origin="issn-inferred">07 Agricultural and Veterinary Sciences</api:keyword><api:keyword scheme="for" origin="issn-inferred">11 Medical and Health Sciences</api:keyword><api:keyword scheme="science-metrix" origin="issn-inferred">Virology</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">32 Biomedical and clinical sciences</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">42 Health sciences</api:keyword></api:keywords></api:all-labels><api:journal issn="0264-410X" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/976912" title="Vaccine"><api:records><api:record source-name="summary"><api:title>Vaccine</api:title></api:record></api:records></api:journal><api:relationships href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/851/relationships"/></api:object></api:result></api:response>